Ayuda
 

Comprar este artículo
Extensión: 8.31 páginas impresas en papel A4

file05.gif (1491 bytes)
Artículos seleccionados para su compra


INFECCION AGUDA POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA. ESTADO ACTUAL DE LOS CONOCIMIENTOS Y PREGUNTAS AUN PENDIENTES
(especial para SIIC © Derechos reservados)
= A pesar de los avances en relación con la patogenia y el tratamiento de la infección por este virus, aún hay debate acerca de la mejor estrategia de manejo durante las primeras etapas que siguen a la infección.
Autor:
Hyang Nina Kim
Columnista Experto de SIIC
Artículos publicados por Hyang Nina Kim
Coautor
Connie Celum* 
MD MPH, University of Washington*
Recepción del artículo
8 de Abril, 2003
Primera edición
30 de Julio, 2003

Resumen
La comprensión de la fisiopatología de la infección aguda y precoz por el virus de la inmunodeficiencia humana (HIV) podría contribuir con el desarrollo de nuevas estrategias destinadas a modificar el índice de progresión de la enfermedad y reducir la transmisión secundaria. En este artículo, revisamos los hallazgos clínicos y los criterios diagnósticos de la infección aguda y precoz por HIV, resumimos los datos de trabajos clínicos en marcha en relación con el tratamiento de ambas situaciones y discutimos la problemática actual respecto de los beneficios y toxicidad de la terapia antirretroviral precoz

Palabras clave
Infección por HIV temprana, infección primaria o aguda por HIV, infección por HIV


Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página  www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Infectología
  Relacionadas: EpidemiologíaAtención PrimariaMedicina InternaDiagnóstico por LaboratorioSalud Pública


Artículo completo

(castellano)
Extensión:  +/-8.31 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Early HIV infection:Current understanding and remaining questions

Abstract
Understanding the pathophysiology of acute and early HIV infection may identify new strategies that alter the rate of disease progression and reduce secondary transmission. In this article, we review the clinical features and diagnostic criteria for acute and early HIV infection, summarize existing data from ongoing clinical trials of treatment of acute and early HIV infection, and highlight the current debates about benefits versus toxicities of early treatment

Key words
Infección por HIV temprana, infección primaria o aguda por HIV, infección por HIV

Full text
(english)
para suscriptores/ assinantes
Bibliografía del artículo
  1. Latin America and the Caribbean: AIDS epidemic update. Geneva: Joint United Nations Programme on HIV/AIDS, World Health Organization, 2002:21-23
  2. Koopman JS, Jacquez JA, Welch GW, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:249-58
  3. Schacker TW, Hughes JP, Shea T, Coombs RW and Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128:613-20
  4. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60
  5. Daar ES, Moudgil T, Meyer RD and Ho DDP. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-4.
  6. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-9
  7. Wawer MJ, Serwadda D, Li X, et al. HIV-1 transmission per coital act, by stage of HIV Infection in the HIV+ index partner, in discordant couples, Rakai, Uganda. In: 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2003
  8. Colfax GN, Buchbinder SP, Cornelisse PG, Vittinghoff E, Mayer K and Celum C. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002;16:1529-35
  9. Bollinger RC, Brookmeyer RS, Mehendale SM, et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA 1997;278:2085-9
  10. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Ann Intern Med 2001;134:761-76
  11. Wilson JD, Ogg GS, Allen RL, et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 2000;14:225-33
  12. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000;181:872-80
  13. Mellors JW, Kingsley LA, Rinaldo CR, Jr., et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9
  14. Schacker T, Collier AC, Hughes J, Shea T and Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257-64
  15. Vanhems P, Allard R, Cooper DA, et al. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive Clin Infect Dis 1997;24:965-70
  16. Lavreys L, Baeten JM, Overbaugh J, et al. Virus load during primary Human Immunodeficiency Virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis 2002;35:77-81
  17. Vanhems P, Lambert J, Cooper DA, et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998;26:323-9
  18. Veugelers PJ, Kaldor JM, Strathdee SA, et al. Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis 1997;176:112-7
  19. Celum CL, Buchbinder SP, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 2001;183:23-35
  20. Horsburgh CR, Jr., Ou CY, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. Lancet 1989;2:637-40
  21. Constantine N. HIV antibody assays: HIV InSite Knowledge Base, 2001. Available at: http://hivinsite.ucsf.edu/InSite.jsppage=kb-02-02-01
  22. Parekh BS, Hu DJ, Vanichseni S, et al. Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses 2001;17:453-8
  23. Constantine NT, Sill AM, Jack N, et al. Improved classification of recent HIV-1 infection by employing a two-stage sensitive/less-sensitive test strategy. J Acquir Immune Defic Syndr 2003;32:94-103
  24. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998;280:42-8
  25. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13
  26. Berrey MM, Schacker T, Collier AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001;183:1466-75
  27. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C and Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997;175:1051-5
  28. Lillo FB, Ciuffreda D, Veglia F, et al. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. AIDS 1999;13:791-6
  29. Kaufmann GR, Zaunders JJ, Cunningham P, et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000;14:2643-51
  30. Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000;181:121-31
  31. Smith D, Berrey MM, Robertson M, et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000;182:950-4
  32. Yerly S, Kaiser L, Perneger TV, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000;14:243-9
  33. Kinloch S, Cooper D, Lampe F, et al. The QUEST cohort: Treatment of primary HIV infection with quadruple HAART: Week 48 preliminary results. In: 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2003
  34. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6
  35. Hecht FM, Wang L, Collier AC, et al. Is HAART for Primary/Early HIV Infection Associated with Improved Outcomes After Treatment Discontinuation In: 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2003
  36. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002;186:634-43
  37. Poggi C, Profizi N, Djediouane A, Chollet L, Hittinger G and Lafeuillade A. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection. AIDS 1999;13:1213-20
  38. Daar ES, Bai J, Hausner MA, Majchrowicz M, Tamaddon M and Giorgi JV. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med 1998;128:827-9
  39. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999;179:527-37
  40. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35
  41. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002;51:1-55
  42. Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 2000;132:306-11
  43. Schacker T, Little S, Connick E, et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis 2000;181:354-7.

 
Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
Clasificado en
Artículos originales>
Expertos del Mundo

Especialidad principal:
Infectología

Relacionadas:
 Epidemiología
 Atención Primaria
 Medicina Interna
 Diagnóstico por Laboratorio
 Salud Pública
Suscripción a siicsalud

Comprar este artículo
Extensión: ± 8.31 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra

Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.

anterior.gif (1015 bytes)


Suscripción a siicsalud


Bienvenidos a siicsalud

Acerca de SIIC     Estructura de SIIC

Sociedad Iberoamericana de Información Científica (SIIC)
Av. Belgrano 430, (C1092AAR), Buenos Aires, Argentina
Tel: +54 11 4342 4901; Fax: +54 11 4331 3305
Casilla de Correo 2568, (C1000WAZ) Correo Central, Buenos Aires
Copyright siicsalud© 1997-2014, Sociedad  Iberoamericana de Información Científica (SIIC)
ISSN siicsalud: 1667-9008
ua4711
Mensajes a SIIC